CLDN18.2 targeting HCAR4 therapy (Immunoadaptive Cell Therapy)

N/A

Report date: 2025/06/11 10:36:17

Base Information

Drug NameCLDN18.2 targeting HCAR4 therapy (Immunoadaptive Cell Therapy)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocytes stimulantsClaudin 18 protein modulatorsImmunostimulants

TargetsClaudin-18 splice variant 2

Therapy Area/IndicationsGastroesophageal Junction NeoplasmsStomach Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIndia

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesImmunoadoptive Cell Therapy Pvt Ltd

China Registration ClassN/A

Develop Information

Active CompaniesImmunoadoptive Cell Therapy Pvt Ltd

Inactive CompaniesN/A

Active IndicationsGastroesophageal Junction NeoplasmsStomach Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A